IRIDEX Launches New Glaucoma Procedure Based on MicroPulse Technology

IRIDEX Corp. has announced the launch of a new glaucoma procedure based on its MicroPulse technology, according to a news release.


The non-invasive, in-office glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty. MLT produces laser pulses at very short durations to create a therapeutic response of lowering the intra-ocular pressure of a glaucoma patient without thermal damage, according to the company. It was first introduced by IRIDEX in its infrared laser platforms; recent technology advancements have made it available with the IRIDEX green laser system.


"Compared to other lasers used for the treatment of glaucoma, the IQ 532 with the MicroPulse module offers greater versatility because it can also be used for a range of other conditions including diabetic macular edema, proliferative diabetic retinopathy, and retinal tears," said David Gossage, MD, medical director of the Gossage Eye Institute, in the release. "I'm comfortable offering MLT to glaucoma patients as a first-line option because of its potential to reduce intraocular pressure without causing tissue damage."


The new glaucoma therapy was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery.


IRIDEX is based in Mountain View, Calif.


Related Articles on Glaucoma:

Bausch + Lomb to Acquire ISTA Pharmaceuticals for $500M

Georgia's Eye Center South Merges With Wall Eye Care

FDA Approves Carl Zeiss Meditec's Cirrus HD-OCT for Dry AMD and Glaucoma

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months